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Brugada Syndrome: A Newly Recognized Sudden Death Syndrome
in Hong Kong
NGAI-SHING MOK
From Cardiology Team, Department of Medicine & Geriatrics, Princess Margaret Hospital, Hong Kong
MOK: Brugada Syndrome: A Newly Recognized Sudden Death Syndrome in Hong Kong. Since Brugada syndrome
was first described in 1991, it has been recognized world-wide as an important cause of sudden cardiac death. The
past decade witnessed a large body of medical literature that has shed light on the epidemiology and pathophysiology
of this peculiar syndrome. In Hong Kong this syndrome was first reported in April 1999. Since then it has been
increasingly identified among local Chinese patients as a cause of sudden arrhythmic death and unexplained syncope
or seizure. Local study on the clinical and genetic aspects of Brugada syndrome is underway. This article reviews
our current understanding of the Brugada syndrome and the clinical profile of local Chinese patients suffering from
this syndrome. (J HK Coll Cardiol 2001;9:144-148)
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Idiopathic ventricular fibrillation (VF) has been
reported to account for 3-9% of all sudden arrhythmic
deaths.1 In 1991, Pedro and Josep Brugada first described
a specific form of idiopathic VF which is now known
as the Brugada syndrome. 2 It is a primary electrical
disease characterized by a marked ST segment elevation
in leads V1-V3 on electrocardiogram (ECG) during sinus
rhythm with or without right bundle branch block (Figure
1) and a propensity for life-threatening ventricular
tachyarrhythmias in the absence of any structural heart
disease. Recognizing the Brugada ECG pattern is easy
when the characteristic coved type or less commonly
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saddle-back type ST segment elevation is present.
However, dynamic changes or transient normalization
of the ST segment may obscure the correct diagnosis.
Shimizu et al.3 recently demonstrated that recognition
of the Brugada ECG pattern may be facilitated by placing
electrodes for leads V1-V2 in the 2nd and 3rd intercostal
spaces (ICS) in addition to the conventional 4th ICS.
Sodium channel blockers including flecainide,
procainamide and ajmaline were shown to be effective
in unmasking the syndrome in affected subjects who
had normal baseline ECG.4 Whenever a typical Brugada
ECG pattern is identified, any underlying structural heart
disease should be ruled out by imaging techniques,
cardiac catheterization and/or endomyocardial biopsy
before the diagnosis of Brugada syndrome can be
established. Patients with Brugada syndrome may
present with syncope, convulsion or sudden cardiac
death. However, they may be totally asymptomatic with
their Brugada ECG pattern only discovered incidentally
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Figure 1. 12-lead surface electrocardiogram in a patient with Brugada syndrome demonstrating the typical RBBB pattern
and down-sloping coved type ST-segment elevation in leads V1-V3 (arrows) followed by inverted T waves.

or found during family screening for Brugada syndrome.
Although Brugada syndrome is mainly found in adults
with a male predominance, children are not immune.5
In fact this syndrome may account for the death of some
victims of the sudden infant death syndrome.
In the past decade, results of numerous clinical
and basic scientific research studies on this peculiar
syndrome have gradually unraveled its mystery. It is
now known that this syndrome is genetically determined
with an autosomal dominant pattern of transmission.
Genetic data has linked this syndrome to mutations in
cardiac sodium channel gene SCN5A in chromosome 3.6
The ionic basis and arrhythmia mechanisms in
Brugada syndrome have been elegantly described by
Antzeletvitch.7 It is the loss of action potential dome in
right ventricular epicardium but not endocardium which
underlies the ST segment elevation in this syndrome.
Sodium channel blockers by enhancing the loss of action
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potential dome can augment or unmask the ST segment
elevation in affected subjects. The electrical
heterogeneity across the wall of the right ventricular
outflow tract provides a substrate for phase 2 reentry
between endocardial and epicardial layers that leads to
polymorphic ventricular tachycardia (VT) or VF and
sudden cardiac death.
Prognosis is poor for symptomatic patients with
this syndrome. Brugada et al.8 reported a 60% recurrence
of arrhythmic events among symptomatic patients over
a 4-year follow-up. However, the prognosis for
asymptomatic subjects is uncertain. Latest data from
Brugada et al.8 showed an 8% event rate in asymptomatic
patients in the 3 years after recognition of the abnormal
ECG. On the contrary, other groups from Italy and Japan
reported no clinical events among their asymptomatic
patients over a mean follow-up period of 15-42.5
months.9-11 To date, implantable cardioverter-defibrillator
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(ICD) is the only effective intervention for preventing
sudden death in symptomatic patients with Brugada
syndrome while anti-arrhythmic drugs including
amiodarone and beta-blockers were found not useful.12
Use of quinidine at a dose that can render previously
inducible polymorphic VT or VF non-inducible in
electrophysiology study was shown to be useful in a
retrospective study by Belhassen et al.13 to prevent VF
recurrence in patients with idiopathic VF or Brugada
syndrome. However, as data from prospective
randomized trials are lacking, routine use of quinidine
in the treatment of Brugada syndrome is therefore not
recommended. As for the optimal management of those
patients who are asymptomatic, there is as yet no
consensus. While Brugada et al. 14 advocated the
prophylactic implantation of an ICD in asymptomatic
patients who have a history of familial sudden death or
are inducible into polymorphic VT or VF by means of
programmed ventricular stimulation, Priori et al. 10
favoured a more conservative use of ICDs and a more
accurate monitoring of asymptomatic individuals using
insertable loop recorders in light of their own findings
that these patients are at a much lower risk for sudden
death than previously described.
Brugada syndrome appeared to be ubiquitous but
it was only rarely reported in Chinese patients. The first
three cases of Brugada syndrome in Chinese were
reported by Teo et al. in 1998. 15 Although Brugada
syndrome was first described in 1991, it was not until

April 1999 when the first two local Chinese patients
with Brugada syndrome were reported in medical
literature.16,17 The first patient was a 52-year-old male
who presented with recurrent nocturnal seizures. Holter
monitoring recorded a self-terminating VF which lasted
2.5 minutes and was accompanied by seizure and loss
of consciousness. The second patient was a 29-year-old
male who survived a sudden cardiac death due to VF.
Both patients received ICD implants and experienced
appropriate shocks for polymorphic VT or VF during
the follow-up period (Figure 2). Naturally one would
ask why it took 8 years before Brugada syndrome could
be identified for the first time in Hong Kong. Is it because
Brugada syndrome is rare among Hong Kong Chinese
or was it just underdiagnosed in the past? To answer
this question, we initiated a local multicentre prospective
study on Brugada syndrome in September 1999 on
behalf of the Hong Kong Interhospital Network of
Pacing and Cardiac Electrophysiology (HK-IN-PACE).
Patients with Brugada ECG pattern were enrolled and
their clinical characteristics studied. Genetic study in
collaboration with Professor SG Priori in Italy was also
performed in our patients to look for any mutation in
the cardiac sodium channel gene SCN5A in chromosome
3. An interim report of the study was presented in the
Hong Kong College of Cardiology 9th Annual Scientific
Congress.18 As of January 2001, a total of 40 patients
were enrolled into the study from 5 regional hospitals.
Seventeen patients were symptomatic and 23

Figure 2. Stored electrocardiogram in ICD (continuous strip) implanted in a symptomatic patient with Brugada
syndrome showing an episode of polymorphic VT correctly detected and successfully cardioverted by an electric shock
of 15 Joules (arrow) delivered by the ICD.
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asymptomatic prior to their enrollment. All symptomatic
patients had a history of syncope and 5 of them had
survived sudden cardiac death. Of the 23 patients who
were genotyped, 5 (22%) of them were found to have
mutation in their SCN5A gene (unpublished data). Seven
symptomatic patients received ICD implants while 5
were put on antiarrhythmic agents. On the contrary only
1 asymptomatic patient received treatment with ICD.
Notably, 1 symptomatic patient presented in 1989 at
the age of 44 with sudden VF arrest but was misdiagnosed as acute myocardial infarction. His ECG
during sinus rhythm showed ST segment elevation in
leads V1-V3 which could be augmented after flecainide
provocation. Subsequent work-up ruled out structurally
heart disease and symptomatic Brugada syndrome
presenting with VF was diagnosed in retrospect in that
patient. Thus Brugada syndrome could be found in Hong
Kong in as early as 1989, even before this syndrome
was first described in literature.
In one quarter of our enrolled patients, the
Brugada ECG pattern was not visible on routine 12-lead
ECG but could be uncovered by flecainide provocation
test (FPT). Recently we reported our experience in

Princess Margaret Hospital in using FPT to unmask
Brugada syndrome in Chinese patients with a concealed
form of the syndrome.19 During FPT, flecainide at a
dosage of 2 mg/kg not exceeding 150 mg was given
intravenously over 10 minutes under continuous cardiac
monitoring. A positive test was defined as occurrence
of terminal R wave and >1 mm ST segment elevation in
leads V1-V3 after flecainide infusion. From February
1999 to December 2000, a total of 26 subjects with
normal baseline ECG have undergone FPT. None had
structural heart disease. Thirteen of these 26 subjects
had a positive FPT (M:F 11:2, mean age 45±16 years).
Among these 13 subjects, 5 were family members of
patients with known Brugada syndrome and 3 were
previously labeled as suffering from syncope of
unknown origin. In 4 subjects, the FPT was positive only
when leads V1-V2 were recorded in 2nd and 3rd ICS at
the level of right ventricular outflow tract instead of the
conventional 4th ICS. (Figure 3). Among those with
positive FPT, the maximum rise in ST segment was
seen in lead V2 (1.7±0.9 mm in V1, 2.5±1.1 mm in V2 &
1.5±0.8 mm in V 3). During FPT, only 3 subjects
experienced transient nausea and dizziness that did not

Figure 3. Results of flecainide provocation test in a patient with unexplained syncope. No significant rise in ST-segment
during flecainide infusion when leads V1-V2 was recorded in the 4th ICS (left panel). Typical Brugada ECG pattern was
unmasked by flecainide when leads V1-V2 was recorded in 2nd ICS (right panel).
J HK Coll Cardiol, Vol 9
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require treatment and transient unifocal ventricular
ectopic beats were found in 3 subjects who had a positive
FPT. No VF or significant bradyarrhythmia was
documented in any of the subjects during the test.
In conclusion, Brugada syndrome is newly
recognized in Hong Kong as a cause of sudden cardiac
death. Local data suggested that this syndrome is not
rare but grossly underdiagnosed in the past in Hong
Kong. A history of unexplained syncope, seizure or
cardiac arrest in young healthy adults should raise the
suspicion of this peculiar syndrome, particularly when
patients have a family history of sudden death.
Recognition of the typical ECG pattern and judicious
use of FPT in clinically suspicious patients should help
in improving the diagnostic yield in our local patients.
Appropriate management of these patients will improve
their prognosis. Local experience in using FPT to
unmask the Brugada ECG pattern in patients with
concealed form of the syndrome was consistent with
the overseas experience that this test, when used
appropriately, is both useful and safe. Electrodes for
recording leads V1-V2 should be positioned in 2nd and
3rd ICS in addition to 4th ICS during FPT to improve
its sensitivity in identifying patients with Brugada
syndrome.
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